MA34014B1 - Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux - Google Patents

Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux

Info

Publication number
MA34014B1
MA34014B1 MA35162A MA35162A MA34014B1 MA 34014 B1 MA34014 B1 MA 34014B1 MA 35162 A MA35162 A MA 35162A MA 35162 A MA35162 A MA 35162A MA 34014 B1 MA34014 B1 MA 34014B1
Authority
MA
Morocco
Prior art keywords
compounds
cancer agent
peripheral nerve
nerve disorders
disorders induced
Prior art date
Application number
MA35162A
Other languages
Arabic (ar)
English (en)
Inventor
Naomi Kitamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34014(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA34014B1 publication Critical patent/MA34014B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un médicament qui réprime (ou mitige) divers symptômes neurologiques provoqués par un trouble nerveux périphérique induit par un agent anticancéreux.
MA35162A 2010-01-27 2011-01-26 Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux MA34014B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
PCT/JP2011/052077 WO2011093512A1 (fr) 2010-01-27 2011-01-26 Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux

Publications (1)

Publication Number Publication Date
MA34014B1 true MA34014B1 (fr) 2013-02-01

Family

ID=43770309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35162A MA34014B1 (fr) 2010-01-27 2011-01-26 Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux

Country Status (41)

Country Link
US (5) US20130046000A1 (fr)
EP (1) EP2528598B1 (fr)
JP (2) JP6131046B2 (fr)
KR (1) KR20120118044A (fr)
CN (2) CN104744321A (fr)
AR (1) AR080024A1 (fr)
AU (1) AU2011211294B2 (fr)
BR (1) BR112012018434A2 (fr)
CA (1) CA2788150C (fr)
CL (1) CL2012002079A1 (fr)
CO (1) CO6592110A2 (fr)
CR (1) CR20120412A (fr)
CY (1) CY1117268T1 (fr)
DK (1) DK2528598T3 (fr)
DO (1) DOP2012000209A (fr)
EA (1) EA201290697A1 (fr)
EC (1) ECSP12012126A (fr)
ES (1) ES2560215T3 (fr)
GE (1) GEP20166441B (fr)
HK (1) HK1177423A1 (fr)
HR (1) HRP20160165T1 (fr)
HU (1) HUE027310T2 (fr)
IL (1) IL221066A (fr)
MA (1) MA34014B1 (fr)
ME (1) ME02364B (fr)
MX (1) MX2012008514A (fr)
MY (1) MY163936A (fr)
NZ (1) NZ601635A (fr)
PE (1) PE20121694A1 (fr)
PL (1) PL2528598T3 (fr)
PT (1) PT2528598E (fr)
RS (1) RS54591B1 (fr)
SG (2) SG10201503402XA (fr)
SI (1) SI2528598T1 (fr)
SM (1) SMT201600103B (fr)
TN (1) TN2012000364A1 (fr)
TW (1) TWI481401B (fr)
UA (1) UA109540C2 (fr)
UY (1) UY33203A (fr)
WO (1) WO2011093512A1 (fr)
ZA (1) ZA201205681B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2602810C2 (ru) 2012-04-27 2016-11-20 Ниппон Дзоки Фармасьютикал Ко., Лтд. Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
KR20160089531A (ko) * 2013-12-17 2016-07-27 제넨테크, 인크. Pd-1 축 결합 길항제 및 항-her2 항체를 사용하여 her2-양성 암을 치료하는 방법
AR104539A1 (es) 2015-05-08 2017-07-26 Takeda Pharmaceuticals Co Compuestos cíclicos
CA2986263A1 (fr) 2015-06-17 2016-12-22 Genentech, Inc. Procedes de traitement de cancers du sein metastatiques ou a un stade localement avance a l'aide d'antagonistes se liant a l'axe pd-1 et de taxanes
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
EP3679925B1 (fr) * 2017-09-07 2024-10-23 Shenzhen Salubris Pharmaceuticals Co. Ltd Composition pharmaceutique de conjugué de docétaxel et procédé de préparation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
EP0252146B1 (fr) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Facteurs nucleaires associes a la regulation de la transcription
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (fr) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Methode d'expression de gene inductible
WO1989007614A1 (fr) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Facteurs nucleaires associes a la regulation de la transcription
WO1989008147A1 (fr) 1988-03-01 1989-09-08 Whitehead Institute For Biomedical Research ACTIVATION DU PRECURSEUR NF-kB
JP3479532B2 (ja) 1989-03-31 2003-12-15 ザ・チルドレンズ・メディカル・センター・コーポレーション エイズの痴呆症、脊髄障害および失明の治療
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
JPH06500554A (ja) 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療
WO1992017168A1 (fr) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Procede permettant d'empecher les lesions neuronales dues aux recepteurs de n-methyl-d-aspartate
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
EP0581856B1 (fr) 1991-04-19 1999-07-14 The Children's Medical Center Corporation Procede de prevention des atteintes neuronales dues au complexe recepteur n-methyle-d-aspartate (nmda)
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
JPH11506770A (ja) * 1995-06-07 1999-06-15 スーゲン，インコーポレーテッド アダプタプロテイン／チロシンキナーゼ相互作用を阻害するための方法および組成物
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
JP4319348B2 (ja) 1997-10-17 2009-08-26 ジェネンテック・インコーポレーテッド ヒトトール相同体
AU1539399A (en) 1997-11-25 1999-06-15 Medical University Of South Carolina Inhibitors of nitric oxide synthase
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (fr) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
PT1063228E (pt) 1998-03-09 2005-05-31 Takeda Pharmaceutical Derivados de cicloalcenos processo para a sua preparacao e utilizacao
EP1209149B9 (fr) 1999-08-06 2011-08-31 Takeda Pharmaceutical Company Limited Composes a cycle aromatique substitues, procede de production, et utilisation
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
WO2001056562A1 (fr) 2000-02-04 2001-08-09 Takeda Chemical Industries, Ltd. Compositions d'emulsions stables
AU6488901A (en) 2000-05-25 2001-12-03 Schering Corp Human receptor proteins; related reagents and methods
CA2685447C (fr) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Composition pharmaceutique
DE60144570D1 (de) 2000-10-18 2011-06-16 Takeda Pharmaceutical Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese
US6762496B2 (en) 2000-11-30 2004-07-13 Tokuyama Corporation Substrate and production method therefor
AU2002221099A1 (en) 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
US7960416B2 (en) 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
WO2003084527A1 (fr) 2002-04-08 2003-10-16 Takeda Chemical Industries, Ltd. Agent therapeutique pour la prevention d'etat septique grave
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040259790A1 (en) 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
EP1599726A4 (fr) 2003-02-27 2009-07-22 3M Innovative Properties Co Modulation selective d'une activite biologique induite par le recepteur tlr
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20050059072A1 (en) 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
TWI404529B (zh) 2005-06-03 2013-08-11 Ono Pharmaceutical Co 神經再生及／或保護劑
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007091790A1 (fr) 2006-02-07 2007-08-16 Korea Institute Of Radiological & Medical Sciences Composition destinée au traitement d'une lésion du système nerveux central ou périphérique
WO2007100650A2 (fr) 2006-02-23 2007-09-07 Yale University Résistance aux médicaments et solutions thérapeutiques
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
EP1997902B1 (fr) 2006-03-30 2013-09-18 Hiroshima University Procédé de criblage
WO2007123186A1 (fr) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited Produit pharmaceutique
EP2018855A1 (fr) 2006-05-15 2009-01-28 Takeda Pharmaceutical Company Limited Agent pharmaceutique
JPWO2008004673A1 (ja) 2006-07-07 2009-12-10 武田薬品工業株式会社 シクロアルケン誘導体、その製造法および用途
EP1882687A1 (fr) * 2006-07-27 2008-01-30 Amorepacific Corporation Composés hétérocycliques, leur utilisation comme antagonistes du récepteur vanilloide et les compositions pharmaceutiques qui les contiennent
WO2008112887A1 (fr) 2007-03-13 2008-09-18 Musc Foundation For Research Development Procédés de traitement du diabète sucré de type 1
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
US20100239523A1 (en) 2007-10-30 2010-09-23 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
EP2480536B1 (fr) 2009-09-23 2014-08-13 The Regents of the University of Colorado, A Body Corporate Modulateurs des récepteurs de type toll et leurs utilisations

Also Published As

Publication number Publication date
CO6592110A2 (es) 2013-01-02
AU2011211294A2 (en) 2012-10-04
PE20121694A1 (es) 2012-12-06
IL221066A (en) 2016-10-31
US20130046000A1 (en) 2013-02-21
CL2012002079A1 (es) 2012-12-21
CN102821763A (zh) 2012-12-12
AU2011211294A1 (en) 2012-09-20
NZ601635A (en) 2013-06-28
PL2528598T3 (pl) 2016-06-30
TN2012000364A1 (en) 2014-01-30
TWI481401B (zh) 2015-04-21
JP2016175903A (ja) 2016-10-06
CA2788150C (fr) 2017-06-06
BR112012018434A2 (pt) 2016-04-19
CA2788150A1 (fr) 2011-08-04
ME02364B (fr) 2016-06-20
EA201290697A1 (ru) 2013-02-28
ES2560215T3 (es) 2016-02-17
GEP20166441B (en) 2016-03-10
SG182522A1 (en) 2012-08-30
HRP20160165T1 (hr) 2016-03-11
ECSP12012126A (es) 2012-09-28
EP2528598A1 (fr) 2012-12-05
SG10201503402XA (en) 2015-06-29
SI2528598T1 (sl) 2016-04-29
MY163936A (en) 2017-11-15
AR080024A1 (es) 2012-03-07
DK2528598T3 (en) 2016-03-07
EP2528598B1 (fr) 2016-01-13
KR20120118044A (ko) 2012-10-25
HUE027310T2 (en) 2016-10-28
UY33203A (es) 2011-08-31
UA109540C2 (uk) 2015-09-10
CR20120412A (es) 2012-11-13
SMT201600103B (it) 2016-04-29
DOP2012000209A (es) 2012-12-31
US8901171B2 (en) 2014-12-02
ZA201205681B (en) 2013-09-25
RS54591B1 (en) 2016-08-31
JP2013518032A (ja) 2013-05-20
AU2011211294B2 (en) 2014-11-13
WO2011093512A1 (fr) 2011-08-04
US20130345304A1 (en) 2013-12-26
US20150203464A1 (en) 2015-07-23
JP6131046B2 (ja) 2017-05-17
CN102821763B (zh) 2017-09-22
MX2012008514A (es) 2012-08-17
CY1117268T1 (el) 2017-04-26
TW201130482A (en) 2011-09-16
PT2528598E (pt) 2016-03-04
CN104744321A (zh) 2015-07-01
HK1177423A1 (zh) 2013-08-23
US20160166526A1 (en) 2016-06-16
US20150051256A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
MA34014B1 (fr) Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux
IN2012DN02149A (fr)
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MX2015005174A (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
MA34593B1 (fr) Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral
BR112015009649A2 (pt) composto de triazolo
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201170831A1 (ru) Аминопиразольное соединение
EA201590863A1 (ru) Пролекарства с минимальной токсичностью
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
MA37438A1 (fr) Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora
CL2015003668A1 (es) Método de tratamiento de trastornos neurodegenerativos.
GB2501403A (en) 3-Arylethynyl substituted quinazolinone compounds
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
TH131405B (th) สารประกอบสำหรับระงับอาการผิดปกติเส้นประสาทรอบนอกที่ชักนำโดยสารต้าน มะเร็ง
GB201206984D0 (en) New therapeutic use
FR2992963A1 (fr) Precurseurs organosilanes polysilyles fonctionnalisables
BR112015001515A2 (pt) compostos terapêuticos
TH131405A (th) สารประกอบสำหรับระงับอาการผิดปกติเส้นประสาทรอบนอกที่ชักนำโดยสารต้านมะเร็ง
MA39074B1 (fr) Polythérapie avec un anticorps anti-ang 2 et un agoniste cd40